Risperidone in adolescent schizophrenic psychoses: A retrospective study

International Journal of Psychiatry in Clinical Practice

Volumn 11, Issue 4, 2007, Pages 273-278

  Hrdlicka, Michal ^a   Dudova, Iva ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Adolescence; Atypical antipsychotics; Childhood; Schizophrenia

Indexed keywords

AMITRIPTYLINE; ARIPIPRAZOLE; BROMAZEPAM; CARBAMAZEPINE; CHLORPROMAZINE; CHLORPROTHIXENE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOMIPRAMINE; CLONAZEPAM; DOSULEPIN; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE; HALOPERIDOL; LEVOMEPROMAZINE; MOCLOBEMIDE; OLANZAPINE; PERPHENAZINE; PIMOZIDE; RISPERIDONE; SERTRALINE; SULPIRIDE; THIORIDAZINE; TIAPRIDE; TRIFLUOPERAZINE; ZIPRASIDONE; ZOTEPINE; ZUCLOPENTHIXOL;

ADOLESCENT; ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DYSKINESIA; DYSPHAGIA; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; FEMALE; GALACTORRHEA; GASTROINTESTINAL DISEASE; HOSPITALIZATION; HUMAN; HYPERSALIVATION; HYPOTENSION; INCREASED APPETITE; MALE; MEDICAL RECORD; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TREATMENT RESPONSE; TREMOR;

EID: 36248941513     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500701246054     Document Type: Article

References (34)

1. Findling RL, Steiner H, Weller EB. Use of antipsychotics in children and adolescents. J Clin Psychiatry 2005;66(Suppl 7):29-40.
2. Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996;53:1090-7.
3. Frazier JA, Gordon CT, McKenna K, Lenane MC, Jih D, Rapoport JL. A open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1994;33:658-63.
4. Turetz M, Mozes T, Toren P, et al. An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia. Br J Psychiatry 1997;170:507-10.
5. Kranzler H, Roofeh D, Gerbino-Rosen G, et al. Clozapine: its impact on aggressive behavior among children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2005;44:55-63.
6. Remschmidt H, Schultz E, Martin PDM. An open trial of clozapine in thirty six adolescents with schizophrenia. J Child Adolesc Psychopharmacol 1994;4:31-41.
7. Quintana H, Keshavan M. Case study: risperidone in children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 1995;34:1292-6.
8. Armenteros JL, Whitaker AH, Welikson M, Stedge DJ, Gorman J. Risperidone in adolescents with schizophrenia: an open pilot study. J Am Acad Child Adolesc Psychiatry 1997;36:694-700.
9. Hrdlicka M, Propper L, Vinar O, et al. Risperidone in the acute treatment of schizophrenia in adolescence [in Czech]. Cesk Slov Psychiat 1998;94:131-8.
10. Drtilkova I. Risperidone in children and adolescents with psychotic disorders of the schizophrenic type [in Czech]. Cesk Slov Psychiat 1999;95(Suppl 2):22-9.
11. Zalsman G, Carmon E, Martin A, Bensason D, Weizman A, Tyano S. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. J Child Adolesc Psychopharmacol 2003;13:319-27.
12. Grcevich SJ, Findling RL, Rowane WA, Friedman L, Schulz SC. Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. J Child Adolesc Psychopharmacol 1996;6:251-7.
13. Kumra S, Jacobsen LK, Lenane M, et al. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry 1998;37:377-85.
14. Sholevar EH, Baron DA, Hardie TL. Treatment of childhood-onset schizophrenia with olanzapine. J Child Adolesc Psychopharmacol 2000;10:69-78.
15. Findling RL, McNamara N, Youngstrom EA, Branicky LA, Demeter CA, Schultz SC. A prospective, open-label trial of olanzapine in adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2003;42:170-5.
16. Mozes T, Greenberg Y, Spivak B, Tyano S, Weizman A, Mester R. Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: open-label study. J Child Adolesc Psychopharmacol 2003;13:311-7.
17. Ross RG, Novins D, Farley GK, Adler LE. A 1-year open-label trial of olanzapine in school-age children with schizophrenia. J Child Adolesc Psychopharmacol 2003;13: 301-9.
18. Maagensen M, Aarkrog T. Treatment of adolescent psychoses with olanzapine. Nord J Psychiatry 1999;53:435-8.
19. Propper L, Hrdlicka M, Bares M. Olanzapine in the treatment of psychoses in adolescence [in Czech]. Cesk Slov Psychiat 2001;97:343-9.
20. Shaw JA, Lewis JE, Pascal S, et al. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 2001;11:415-24.
21. McConville B, Carrero L, Sweitzer D, et al. Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial. J Child Adolesc Psychopharmacol 2003;13:75-82.
22. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004;29: 133-45.
23. Gothelf D, Apter A, Reidman J, et al. Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. J Neural Transm 2003;110:545-60.
24. Armenteros JL, Davies M. Antipsychotics in early onset schizophrenia: systematic review and meta-analysis. Eur Child Adolesc Psychiatry 2006;15:141-8.
25. Connor DF, Fletcher KE, Wood JS. Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry 2001;62:967-74.
26. World Health Organization. International classification of diseases. 10th ed. Geneva: WHO; 1992.
27. National Institute of Mental Health. Clinical Global Impression (CGI). Psychopharmacol Bull 1985;21:839-840.
28. Kasper S, Rosillon D, Duchesne I. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. Int Clin Psychopharmacol 2001;16:179-87.
29. Kasper S, Rosillon D, Duchesne I. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study. Int Clin Psychopharmacol 2001;16:189-96.
30. Aman MG, DeSmedt G, Derivan A, Lyons B, Findling RL and Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002;159:1337-46.
31. Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 2002;41:1026-36.
32. Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 2006;163:402-10.
33. Research Unit on Pediatric Psychopharmacology Autism Network, McCracken JT, et al. Risperidone in children with autism and serious behavioral problems. New Engl J Med 2002;347:314-21.
34. Shea S, Turgay A, Caroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autism and other pervasive developmental disorders. Pediatrics 2004;114:634-41.